RealTalk MS

Main Content

Photo courtesy of National MS Society

RealTalk MS Is On Right Now!

Join host Jon Strum each week as he breaks down the latest multiple sclerosis news. We’re talking about the amazing MS research that’s taking place in laboratories around the world — and we’re talking to some of the brilliant neuroscientists who are conducting that research!

We’re monitoring the debate among our lawmakers surrounding prescription drug price transparency, healthcare legislation, funding for new and experimental MS research — anything that might impact your MS treatments.

And we’re talking with MS activists, MS caregivers, MS fundraisers, and other heroes who strive to raise the bar for those who battle MS every day.

If you’re affected by multiple sclerosis — as a patient, caregiver, family member, or friend — join us for RealTalk MS.

Episode 449: Putting People Affected by MS at the Center of MS Research with Sara Loud, Stephanie Buxhoeveden, and Hollie Schmidt


When you join the iConquer MS community, you're no longer just a patient; you become a research partner. Not just a data point in someone's study. You become the person to suggest the study, to help define the study, and to participate in sharing the outcome of the study.

I Conquer MS

In this week's episode, I talk with the iConquer MS leadership team about what it means to be part of this people-powered research revolution and how iConquer MS keeps people affected by MS at the center of MS research.

The National Institutes of Health has just published a Strategic Plan for Disability Health Research. We're sharing all the details.

And a research team analyzed data from 20 global studies to determine whether anti-CD20 disease-modifying therapies (Ocrevus, Kesimpta, Briumvi) were cost-effective. We're sharing their somewhat surprising results.

And a research team analyzed data from 20 global studies to determine whether anti-CD20 disease-modifying therapies (Ocrevus, Kesimpta, Briumvi) were cost-effective. We're sharing their somewhat surprising results.

We have a lot to talk about! Are you ready for RealTalk MS??!

This Week: We're talking about people-powered MS research  :22

The NIH has published a Strategic Plan for Disability Health Research  1:15

Researchers determine whether anti-CD20 disease-modifying therapies (Ocrevus, Kesimpta, Briumvi) are cost-effective  6:05

Sara Loud, Stephanie Buxhoeveden, and Hollie Schmidt discuss what it means to put people affected by MS at the center of MS research  12:41

Share this episode  36:26

Next week  36:45

SHARE THIS EPISODE OF REALTALK MS

Just copy this link & paste it into your text or email: https://realtalkms.com/449

ADD YOUR VOICE TO THE CONVERSATION

I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!

Email: jon@realtalkms.com
Phone: (310) 526-2283

And don't forget to join us in the RealTalk MS Facebook group!

LINKS

If your podcast app doesn't allow you to click on these links, you'll find them in the show notes at www.RealTalkMS.com

iConquer MS
https://iconquerms.org

National Institutes of Health Strategic Plan for Disability Health Research
https://dpcpsi.nih.gov/disabilityhealthresearch

STUDY: Economic Value of Anti-CD20 Therapies in Multiple Sclerosis: A Systematic Review of Cost-Effectiveness Studies
https://journals.sagepub.com/doi/10.1177/17562864261426816

AbleNOW
https://ablenow.com

JOIN: The RealTalk MS Facebook Group
https://facebook.com/groups/realtalkms

REVIEW: Give RealTalk MS a rating and review
http://www.realtalkms.com/review

Follow RealTalk MS on X, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.

RealTalk MS Episode 449
Guests: Sara Loud, Stephanie Buxoeveden, and Hollie Schmidt